Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... -- Bayer HealthCare announced today that it has contributed ... the American Society of Clinical Oncology (ASCO) to support ... to unlock vast quantities of information about the experiences ... is proud to join ASCO and the Conquer Cancer ... help people whose lives have been affected by cancer," ...
(Date:3/5/2015)... 5, 2015   AMC Health , the ... for improving the effectiveness and efficiency of healthcare ... Anazagasty and Jared Wilstead have ... President, Strategic Client Development, and Wilstead will serve ... AMC Health,s commitment to accelerating the adoption of ...
(Date:3/5/2015)... , March 5, 2015 LUNGevity Foundation, ... Food and Drug Administration,s (FDA) approval of Bristol ... and other immunotherapy treatments add another critical new ... the power of a patient,s own immune system ... been approved specifically for patients with squamous cell ...
Breaking Medicine Technology:Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3
... Pharmaceuticals, Inc. (Nasdaq: CADX ), a ... proprietary product candidates principally for use in the ... present a corporate overview at the following investment ... Stanley Global Healthcare ConferenceDate:  Tuesday, September 14, 2010 ...
... 7 UBM TechInsights is pleased to announce it ... Business Development, Medical Devices. In this role Mr. Johnson ... business in the Medical Devices sector. ...   http://www.newscom.com/cgi-bin/prnh/20100907/SF60618 ) Mr. Johnson comes to ...
Cached Medicine Technology:Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010 2UBM TechInsights Expands Presence in the Medical Devices Sector 2
(Date:3/6/2015)... Texas (PRWEB) March 06, 2015 First ... 7am today. The new facility is located at 13351 W. ... “Our experienced clinical team is ready 24-7 to provide the ... Dr. Grossman, Facility Medical Director of First Choice Emergency Room ... ribbon cutting with the South Metro Denver Chamber of Commerce ...
(Date:3/6/2015)... March 06, 2015 Truly Nolen, the ... to announce the grand opening of their first independently-owned ... area down to the Fort Mill – Rock Hill, ... February 27th, 2015 at their new location. ... years of collective experience in the pest control industry. ...
(Date:3/6/2015)... The Gluten-Free Certification Program (GFCP), ... pleased to announce that Dufflet Pastries, the ground-breaking ... their product line of gluten-free treats certified by ... as satisfying as any of their other desserts! ... contains hydrogenated fats or oils, artificial flavours, colours ...
(Date:3/6/2015)... The producers of Health Briefs TV ... Washington and vicinity. This is a city which is full ... many outdoor activities. It is also a city where healthcare ... hospitals call the city home and provide care from the ... TV program will be broadcast on CBS KLEW-TV during the ...
(Date:3/6/2015)... San Diego, CA (PRWEB) March 06, 2015 ... study findings continue to be discussed, Ford & Associates ... wake of a January 2015 filed lawsuit: Verduzco v. ... Court, Northern District of California. , “In light ... those who have used Benicar to evaluate and explore ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:The Health Briefs TV Show to Air in Spokane, Washington 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4
... who are regularly exposed to moderate to high levels of ... count, according to a study published in the September issue ... with painters and decorators are at highest risk. The only ... low sperm counts and low sperm activity was repeated exposure ...
... with smokers have a relatively poor diet, which adds to ... that second-hand smoke accounts for up to 24 per cent ... smoking - usually because they live with a smoker or ... offset some of the negative effects.// ,Researchers at ...
... has told the British Psychological Society that people who feel ... of the television, or going shopping are more likely to ... to disease.Those on the other hand who feel little or ... ,Researchers asked 30 students aged 18-30 to list enjoyable ...
... Sluggish growth in the first year of a boy's life greatly ... a study of Finnish children. , ,The key factor in heart ... grew in the past. It's long been known that babies with ... heart disease in adulthood as heavier babies.// , ,David Barker, an ...
... to feel drunk than non-smoking drinkers – placing them ... hearts, a new study suggests. ,The study shows nicotine ... a good model for humans.Since alcohol abusers generally "drink to ... an expected level of intoxication, say the researchers from the ...
... pesticides and solvents can further lower fertility among infertile ... may worsen the effect of pre-existing genetic or medical ... findings should be treated with caution because they involved ... farming region in Austria. But they say the dramatic ...
Cached Medicine News:
Lyphochek Hemostasis Control is a multi-analyte control to help monitor coagulation factor assays and selected thrombosis risk assays. Assayed values are available for most major instrumentation....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
Medicine Products: